SMPL Shorts Rebuild After Earnings Drop

SMPL heads into the back end of October with short sellers pressing harder on a stock that just posted its worst single-day reaction in months.

Yesterday's earnings release triggered the most immediate tension: the stock fell 8.9% on October 23, the most recent earnings event with a recorded reaction, and the pattern continued this week. SMPL closed at $9.75 on Tuesday, down 11.3% on the week and down roughly 44% year-to-date. The stock is now trading well below every analyst's published target, which cluster around $11 to $14, though those targets have been cut repeatedly through the year and the gap between price and Street expectations speaks more to persistent fundamental disappointment than to an obvious value opportunity.

Short sellers have moved quickly in the aftermath. SI hit 8.9% of the free float on October 27, up 10.9% on the week and up 6.3% in a single session. That is a meaningful acceleration. The FINRA fortnightly confirmed 8.56 million shares short as of October 15, with days-to-cover running at 4.2. Despite the build, the borrow market is not stressed: cost to borrow remains low at around 0.45%, and availability is ample at 619%, meaning there are roughly six shares still available to borrow for every one already lent out. The 52-week tightest reading was 527%, so the lending pool has rarely been stretched. New shorts can enter without friction. The ORTEX short score has crept to 54.5 from 50.6 ten days ago, a steady climb that reflects the accelerating position build rather than any extreme one-way signal. Overall, the lending setup looks comfortable for bears rather than punishing.

Options positioning is more neutral than the short interest build might suggest. The put/call ratio has eased to 1.68 from a 20-day mean of 1.73, putting it just below its recent average. The ratio had been as high as 2.46 over the past year and was running above 2.0 in late September, so the current reading actually marks a modest unwinding of the defensive hedging that dominated options flows six weeks ago. That contrast is worth noting: short sellers are adding, but options traders appear less alarmed than they were.

The Street has been cutting targets throughout 2026, and the consensus tells a bleak story. Ten analysts cover SMPL; eight hold neutral or equivalent ratings and only two are buyers. The mean target of $12.00 implies roughly 23% above the current price, but the trajectory of revisions matters more than the absolute figure. TD Cowen trimmed its target to $11 in August. Bernstein downgraded the stock to Market Perform in June and cut to $12. UBS moved to $12 in June after cutting again in April from $16. Morgan Stanley's target sat at $24 as recently as April and now stands at $14. The direction of travel is consistently lower. The bear case is straightforward: Atkins sales fell 24.6% with household penetration down 220 basis points, Quest bar share is slipping, and OWYN is losing distribution. FY26 EBITDA guidance was cut to $217 million to $225 million. The bull case rests on Quest's 1.1% net sales growth, rising household penetration in chips and shakes, and management's planned price increases alongside a raised revenue guidance range of $1.345 billion to $1.355 billion. EV/EBITDA at 4.8x and a PE of 5.6x look cheap in isolation, and the earnings yield ranks in the 87th percentile of the universe. But the EV/EBIT factor rank at the 93rd percentile suggests the market is applying a distress discount rather than rewarding the valuation.

One data point from ORTEX's alt data layer is worth flagging without overstating it. The SEC EDGAR buyback filings show remaining buyback authorisation up 234% against Q2 last year, with shares repurchased up 197% year-on-year in the same quarter. That suggests management was actively returning capital even as the business weakened, which either reflects confidence or an absence of better internal uses of cash. Neither dataset has been measured as a leading indicator for SMPL's reported figures, so no inference about the next print is warranted. The buyback fact is context, not a signal.

On the ownership register, director James Kilts made an open-market purchase of 80,000 shares at $12.39 in April, a near-$1 million outlay at a price still 27% above where the stock trades today. Director Clayton Daley added 10,000 shares at $11.78 in May. Both were discretionary purchases, not grants or plan-driven trades. That insider buying cluster was filed as recently as May, though the insider data is now slightly stale as of late July, so the picture has not been updated through the latest earnings. ORTEX forecasts a 55% probability of a share-count decrease in the CRSP US Small index at the December 2026 Quarterly Review, with the rank date falling on December 4 and any trade executing December 22. The estimated selling flow is around $13 million, roughly 0.6 days of normal volume, a modest mechanical overhang but worth monitoring as the rank date approaches.

With the next earnings event pencilled in for January 8, the question over the coming weeks is whether the short interest build plateaus or continues to press higher, and whether management's price-increase and cost-reduction plans produce any observable improvement in the alt-data picture before the next print.